key: cord-0714147-40u4o7wc
authors: Göbölös, Laszlo; Rácz, István; Hogan, Maurice; Remsey-Semmelweis, Ernő; Atallah, Bassam; AlMahmeed, Wael; AlSindi, Fahad; Suri, Rakesh M.; Bhatnagar, Gopal; Tuzcu, Emin Murat
title: The role of renin-angiotensin system activated phagocytes in the SARS-CoV-2 coronavirus infection
date: 2020-12-19
journal: J Vasc Surg
DOI: 10.1016/j.jvs.2020.12.056
sha: 9aba8c666213f9269e3309bc2f507462b3959a67
doc_id: 714147
cord_uid: 40u4o7wc

OBJECTIVES: Management of the pandemic caused by the novel coronavirus SARS-CoV-2 challenges both scientists and physicians to rapidly develop, and urgently assess, effective diagnostic tests and therapeutic interventions. The initial presentation of the disease in symptomatic patients is invariably respiratory, with dry cough being the main symptom, but an increasing number of reports reveal multiple organ involvement. The aim of this review is to summarise the potential role of the renin-angiotensin system activated phagocytes in the pathogenesis of COVID-19 disease. METHODS: Data for this review were identified by searches of PubMed, and references from relevant articles using the search terms “SARS”, “COVID-19”, “renin-angiotensin-system”, “phagocyte”, “reactive free radical”, “antioxidant”, “ARDS”, “thrombosis”, “myocardial”, “ischaemia”, “reperfusion”, “microvascular”, and “ACE2”. Abstracts and reports from meetings were not included in this work. Only articles published in English between 1976 and 2020 were reviewed. RESULTS: The cellular target of SARS viruses is the angiotensin converting enzyme 2, a critical regulating protein in the renin-angiotensin system. The elimination of this enzyme by the viral spike protein results in excessive activation of phagocytes, migration into the tissues via the high endothelial venules, and an oxidative burst. In the case of an over-stimulated host immune response, not only devastating respiratory symptoms, but even systemic or multiorgan involvement may be observed. CONCLUSION: Early-stage medical interventions may assist in returning the exaggerated immune response to a normal range; however, some therapeutic delay might result in excessive tissue damages, occasionally mimicking a systemic disease with a detrimental outcome.

1 and SARS-CoV-2, bind the ACE2 enzyme on a different location than its catalytic spot with 2 their spike protein (S-protein), initiating virus internalisation into the ACE2 carrying target The pulmonary RAS pathway, including the antagonising effect of ACE2, has been extensively 6 investigated in both experimental models and clinical investigations, in the context of acute 7 respiratory distress syndrome (ARDS). The potential role of ACE2 in the pathogenesis of severe 8 lung injury has been demonstrated in experiments with ACE2 knock-out mice, having initial 9 healthy lung structure and function. In this investigation, the same dosage of toxin on the lungs 10 of knock-out mice resulted in more severe histological and functional changes compared with 11 those seen in wild type control specimens. The wild type mice after infection with SARS virus, 12 or treated with just with its S-protein, behaved similarly to the ACE2 knock-out mice; and an 13 increase in serum ATII levels was detected. Furthermore, the administration of an angiotensin II 14 type 1 (AT1) receptor blocker successfully limited the extent of pulmonary damage in the ACE2 15 depleted cohort 7 . In another animal experiment, following exposure to a lipopolysaccharide 16 toxin, administration of recombinant ACE2 protein significantly improved the partial oxygen 17 pressure with the same ventilation settings and this was associated with a reduction the extent of 18 lung damage 7,12 . The preventive effect of ACE2 against ARDS has been demonstrated in infants 19 suffering from meconium aspiration, where the lung aspirates revealed excessive ACE2 20 breakdown by proteases in cases developing ARDS. This effect was shown to be reversed with 21 the aid of protease inhibitors in experimental settings 13 . In SARS and Middle East Respiratory cultures and murine models, whereas increased production of cytokines (IL-6, IL-8) produced by 1 NFκB signalling has been detected. The latter may play an essential role in the pathogenesis of 2 ARDS 21-23 , and it has to be noted that the AT1 receptor effect is mostly related to the NFkB 3 signalling pathway 17 . Emerging data from the current COVID-19 pandemic suggests that mainly the lower respiratory 8 tract and occasionally the gastrointestinal passage represents the gate of entry for the 9 coronavirus, but it may affect other organs either directly, or secondarily, including the heart, 10 brain and kidneys. This phenomenon can be understood utilising the above described RAS-11 ACE2-proinflammatory pathway. The tissue-related antioxidants defend against adverse effects of free radicals. The primary 13 antioxidants mitigate the production of derived free radicals from initial radicals by modification 14 into less harmful molecules. This group of antioxidants consists of SOD, the enzyme breaking 15 down the superoxide radical into hydrogen peroxide; the glutathione peroxidase amending the 16 hydrogen peroxide and lipid peroxides to harmless substances; and the metal-binding proteins, The secondary antioxidants, e.g., α-tocopherol, β-carotin, uric acid, bilirubin, albumin entrap free 1 radicals to hinder chain reactions and the tertiary line of antioxidants repair the by free radicals 2 damaged biomolecules, i.e., DNA repair enzymes, methionine-sulfoxide reductase, etc 27 . The P-selectin molecules are not available on "resting" endothelium, but highly expressed in granulocytes can damage the endothelial surface leading to initiation of the coagulation 1 cascade 34-37 . The free radicals are known to have a prothrombotic effect, facilitating platelet 2 aggregation by inhibiting antithrombin III 38 and modifying the prostacyclin synthase effect 39 . The role of the phagocyte system and free radical load in ischaemic heart disease, especially 11 reperfusion tissue injury and arrhythmias, is a well-researched field. The effect of SARS-CoV-2 12 infection on the heart is not completely established yet, but there are signs that the coronavirus 13 may also cause myocarditis, and might interfere with pre-existing coronary disease. showed an increased adherence to isolated myocytes and higher free radical discharge 44 In current reports, especially from Europe, most fatalities were observed in the septa-and 19 octogenarian population. There are several debates present regarding this phenomenon; one is 20 undoubtedly a contributor, namely that the elderly usually have chronic comorbidities, and less physiological reserve. On the other hand, with ageing, the responsiveness of the immune system 1 is declining; therefore, age could be a protective factor against the overreaction of the immune 2 system. The experience from the current pandemic suggests that advanced age is associated with 3 worse clinical outcomes, including higher mortality 52 . The authors declare no conflicts of interest, and did not receive any specific funding for this 13 work. consortium. Age-dependent differences in pulmonary host responses in ARDS: a prospective 

Neutrophil 11 induced oxidative injury of cardiac myocytes

CD11b/CD18-ICAM-1 adherence

Effects of late reperfusion on 15 infarct expansion and infarct healing in conscious rats

Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From 19

COVID-19)

Characterization of the heparin-binding properties of IL-6

Anticoagulation in COVID-19

System Inhibitors and risk of death in patients hospitalised with 16

COVID-19: A retrospective Italian cohort study of 43,000 Patients

COVID-19 and the cardiovascular system

Potential role of statins in COVID-19

Immune modulatory effects of statins

Pharmacoepidemiology of non-steroidal 3 anti-inflammatory drugs

Oxypurinol 6 limits myocardial stunning but does not reduce infarct size after reperfusion

Beneficial effects of oxypurinol pretreatment in stunned, 9 reperfused canine myocardium

N-2-mercaptopropionylglycine 12 improves recovery of myocardial function after reversible regional ischemia

Marked reduction of